The duration of dual antiplatelet therapy (DAPT) in patients with myocardial infarction (MI) should be shortened from 1 year to 3 months, according to data from a new randomized, real-world trial. In the DUAL-ACS trial, giving DAPT for the first 3 months after MI and then continuing with single antiplatelet therapy was associated with a strong trend towards lower all-cause mortality than continuing with DAPT for 12 months.  The principal secondary endpoint, cardiovascular death or recurrent MI, did not differ between the two groups, but researchers observed a strong trend towards an increase in major bleeding in patients who received 12 months of DAPT. Unfortunately, the trial was underpowered due to recruitment issues during the COVID-19 pandemic, and none of the results reached significance.

Overall, considerably more success has been achieved in reducing the thrombogenicity of bio-artificial surfaces than in controlling complement activation: For example, surfaces coated with different forms of heparin or PEG are associated with low or negligible activation of coagulation and subsequent platelet loss. Thus, there are numerous surfaces that have low thrombogenicity available that still bear substantial complement-activating capacity. Some of these materials will no doubt be a

This randomised trial will assess a dual-device strategy involving drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation against single-device approaches using either DCB or DES alone.The study will focus on diabetic patients with de novo coronary artery lesions while addressing a gap in treatment, as these patients often face higher rates of stent failure despite advancements in DES technology.

Technological advances have revolutionized the design, development, and manufacturing of advanced implantable CV devices. However, due to insufficient hemocompatibility, they are still associated with devastating complications. Tissue engineering is an emerging field in contemporary health sciences aimed to optimize CV implants. This scope can be achieved through physical or biochemical surface modification of CV implants aimed to mimicking the physiological endothelial tissue function. The biochemical functionalization described above is difficult from economic and regulatory aspects. Microengineering of CV surface topography can be a promising cost-effective strategy.

TraceLink, the end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, has announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply chain, finance, commercial, and IT leaders to master today’s supply chain complexities and prepare for the increasing prevalence of goal-oriented AI systems.

Given the growing strength of the evidence that the benefit-to-risk ratio of antiplatelet therapy following myocardial infarction differs markedly by the variables that increase risk for recurrent thrombosis or bleeding, Bhatt believes that risk scoring strategies will be used increasingly. Rather than “eyeballing” risk factors, he called for an objective approach to match patients to an antiplatelet strategy with an optimal projected balance of benefit to risk.

Central airway stenosis, otherwise defined as airway narrowing, is often associated with prolonged intubation, tracheostomy, stenting, tuberculosis or lung transplant. There are approximately 100,000 tracheo-bronchial stenting and dilation procedures performed annually within the United States. The study will serve as the basis for Airiver Medical’s regulatory submission to the FDA and eventual commercialization of the Airiver Pulmonary DCB in the U.S.

Over a century of progress in surgery, drugs, prevention, and emergency response has driven down death rates from heart disease and stroke.

Concept Medical has announced the enrolment of the first patient in the MAGICAL-SV trial, a US investigational device exemption (IDE) study evaluating its MagicTouch sirolimus-coated balloon (SCB) for the treatment of small coronary vessels, following US Food and Drug Administration (FDA) IDE approval.

While stent length mismatch is much more common and taken less seriously,diameter mismatch can be more problematic since it looks strikingly odd & ugly .Still, one section of cardiologists believes a little amount of oversizing is safe and good. There is equal opposition to this concept as well. It is not surprising , acquired stent-ectasia of coronary artery during PCI ,has both advantages as well as troubling issues.

The self-adaptive anti-coagulant functional modules within the coating was achieved by thrombin-responsive nanogels. By responding to thrombin, the upstream initiator of coagulation-inflammation, the nanogels dynamically regulated anti-coagulant drug delivery, releasing the therapeutic agents in high thrombotic risk conditions while retaining them in low-risk states. To enhance the blockade of coagulation-inflammation loop, the polyphenol epigallocatechin gallate (EGCG) acted as anti-inflammatory functional modules and participated in coating construction as a cross-linking agent.

Through the detection of biochemical markers, we recorded significant alteration in eNOS, ICAM1, and monocyte attachment in EC grown in microchannel having 60o vessel branching angle which correlated with the lower WSS. The present study highlights the importance of blood vessel branching angle as one of the crucial determining factors in governing atherogenic-endothelial dysfunction.

Cellular mechanobiology is an active field of research that nicely complements the more traditional biochemically-centered view of most biological processes. As we have highlighted throughout this review, mechanical forces are particularly diverse, dynamic, and multifaceted in the vascular system, and these forces play a critical role in regulating vascular physiology and pathology. In light of the fact that many of these forces are borne most directly by the endothelium, elucidating the mechanisms governing EC mechanobiology will enhance our understanding of the etiology of various vascular diseases including atherosclerosis, thrombosis, aneurysm formation, and diabetes.

The model demonstrated high diagnostic accuracy in internal and external validation, outperforming cardiologists in a controlled evaluation and showing consistent performance across different care settings and racial and/or ethnic groups. The models were prospectively evaluated in a clinical trial of patients without previous cardiac imaging, successfully identifying previously undiagnosed heart disease. These findings support the potential of artificial intelligence to expand access to heart disease screening at scale. To enable further development and transparency, we have publicly released model weights and a large, annotated dataset linking heart rhythm data to imaging-based diagnoses.

This is the first conditional approval of three types of domestic high-end implanted medical devices obtained by the U.S. FDA through the pre-market approval (PMA) path, marking an important milestone in the overseas going of domestic coronary stents.According to the announcement, the product is developed based on the theory of "the existence of a time window for arterial and vascular trauma healing" pioneered by Saino Medical International. Its design goal is different from the traditional stent that only inhibits smooth muscle proliferation, but aims to accelerate the patient's trauma healing and functional recovery of vascular endothelium.

This product is intended for catheter-directed thrombectomy treatment in patients with acute high-risk pulmonary embolism (PE) or intermediate-risk PE with clinical deterioration, under one of the following conditions:The presence of thrombus in the main pulmonary artery or major branches, with a high risk of bleeding or contraindications to thrombolytic therapy;The presence of thrombus in the main pulmonary artery or major branches, and the patient has failed thrombolysis or aggressive medical therapy.

In summary, in patients with severe aortic stenosis undergoing TAVR, treatment with colchicine was associated with a lower risk of new-onset atrial fibrillation or atrioventricular conduction disturbances requiring the implantation of a permanent pacemaker at 30 days. In addition, a pre-specified imaging analysis demonstrated a significant reduction in subclinical leaflet thrombosis in patients treated with colchicine as compared to placebo. The trial was however prematurely halted due to a higher rate of stroke in patients treated with colchicine. Confirmatory trials with colchicine or other inflammatory agents, i.e. monoclonal antibodies targeting interleukin1-β or interleukin-6 are warranted to corroborate the effect of anti-inflammatory treatment on the incidence of arrhythmias and subclinical leaflet thrombosis after TAVR.

Coronary aneurysm is defined as a focal dilation of the coronary artery that is at least 1.5 times the diameter of an adjacent normal segment.1 The term coronary aneurysm is often interchangeably used with coronary ectasia, which is arbitrarily defined as a more diffuse dilation of the coronary artery of the same dimensional features as an aneurysm.2 Coronary aneurysms and ectasia are observed in at least 5% of patients who underwent coronary imaging.3 Given the recent expansive use of noninvasive coronary artery imaging, especially coronary computed tomography angiography and magnetic resonance imaging angiography, the detection of coronary aneurysm has become more frequent.4

The first-generation bioresorbable scaffolds (BRS) have been associated with higher rates of device-related adverse outcomes in comparison to everolimus-eluting stents. We aimed to evaluate the efficacy and safety of the thinner-strut (100/125 μm) poly-L-lactic acid-based sirolimus-eluting Firesorb BRS in patients with de novo coronary lesions.

The acquired Vascular Intervention business consists of a portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, Teleflex details that key products include the Pantera Lux drug-coated balloon catheter, the novel PK Papyrus covered coronary stent for acute coronary artery perforations, and the Orsiro Mission drug-eluting stent, an ultrathin drug-eluting stent with differentiated clinical features. For peripheral interventions, the portfolio includes the Passeo-18 Lux peripheral drug-coated balloon catheter, Dynetic-35 balloon-expandable cobalt chromium stent, the Pulsar-18 T3 self-expanding 4F stent, and the Oscar peripheral multifunctional catheter system.